Elizabeth Allen
Family · Clinton, MSNPI 1184946170
Payments from drug & device makers
Across 297 payments — averaging $15.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$752
- Pfizer$533
- Lilly USA, LLC$513
- AstraZeneca$319
- Merck$291
- Novartis$280
- plus $2K from 25 others
What the payments were for
- Food & beverage$4,552100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 53 | $752 |
| Pfizer | 39 | $533 |
| Lilly USA, LLC | 38 | $513 |
| AstraZeneca | 20 | $319 |
| Merck | 18 | $291 |
| Novartis | 18 | $280 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $248 |
| Novo Nordisk | 11 | $187 |
| GSK | 12 | $173 |
| Boehringer Ingelheim | 11 | $159 |
| Johnson & Johnson | 7 | $139 |
| Exact Sciences | 7 | $110 |
| Bayer | 6 | $102 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $92 |
| Amgen | 5 | $89 |
| Abbott | 4 | $85 |
| Sunovion Pharmaceuticals Inc. | 4 | $84 |
| Astellas Pharma US Inc | 4 | $60 |
| Axsome Therapeutics, Inc. | 3 | $58 |
| Dexcom, Inc. | 3 | $52 |
| Idorsia Pharmaceuticals US Inc | 3 | $48 |
| Phathom Pharmaceuticals, Inc. | 2 | $30 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| Biohaven Pharmaceuticals, Inc. | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Eyevance Pharmaceuticals LLC | 1 | $16 |
| Hikma Pharmaceuticals USA | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
How this compares
$4,552 in reported general payments places this provider in the 90th percentile of 3,007 family providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 67 | $65,670 |
| EliquisApixaban | 54 | $47,710 |
| MounjaroTirzepatide | 46 | $47,265 |
| XareltoRivaroxaban | 25 | $26,250 |
| JardianceEmpagliflozin | 25 | $22,953 |
| FarxigaDapagliflozin Propanediol | 23 | $20,425 |
| EntrestoSacubitril/Valsartan | 21 | $19,689 |
| MyrbetriqMirabegron | 22 | $19,272 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $8,136 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $8,100 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 11 | $5,418 |
| Praluent PenAlirocumab | 11 | $5,215 |
| Lubiprostone | 27 | $2,007 |
| Rosuvastatin Calcium | 142 | $1,940 |
| Atorvastatin Calcium | 172 | $1,729 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $187 | $65,67067 claims |
| PfizerEliquis | $533 | $47,71054 claims |
| Lilly USA, LLCMounjaro | $513 | $47,26546 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $319 | $28,56136 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $159 | $28,37136 claims |
| Johnson & JohnsonXarelto | $139 | $26,25025 claims |
| NovartisEntresto | $280 | $19,68921 claims |
| Astellas Pharma US IncMyrbetriq | $60 | $19,27222 claims |
| GSKTrelegy Ellipta | $173 | $8,10013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,007 family providers in Mississippi.
Other family in Clinton
- Cinda PerrymanFayette$888K
- Dodie McGeeRaymond$772K
- Gina BurgeJackson$237K
- Christy DavisJackson$208K
- Maranda EversollFlowood$197K
- Dana DelaskiJackson$158K
- Kristin CarrollJackson$158K
- Shannon FryeryOxford$127K
- Nativel CollinsMantachie$73K
- Ashley CocilovaFlowood$72K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.